Download What To Know About Drug Allergy

Document related concepts

Harm reduction wikipedia , lookup

Drug discovery wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Theralizumab wikipedia , lookup

Transcript
Drug Allergy
Seong H. Cho, MD
Assistant Professor of Medicine
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
경희의대 내과 전임 IS 교수
Allergy-Immunology
 Primary immunodeficiency
(ex. CVID)
 Angioedema and urticaria
 Immunologic lung disease
(ex. ABPA, hypersensitivity
pneumonitis)
 Eosinophilc GI disorders
(ex.EoE)
 Hypereosinophilc syndrome
 Mastocytosis
Classification of Drug Reactions
• Type A reactions (Most common)
1. Predictable
2. Related to pharmacologic actions of the drug
3. No specific host factors
Type A Reactions
•
•
•
•
Toxicity - Renal failure from aminoglycosides
Side effect - Sedation from antihistamines
Secondary effect - Diarrhea from antibiotics
Drug Interaction - Theophylline toxicity from
concomitant erythromycin
Type B Reactions
• Unpredictable
• Less Common
• Occur in susceptible individuals
Type B Reactions
• Intolerance - Tinnitus with aspirin
• Idiosyncratic reaction - Hemolysis with
dapsone in G6PD deficiency
• Hypersensitivity (Specific immunologic) Anaphylaxis after penicillin
• Pseudoallergic (non-immunologic) Anaphylactoid reaction to radiocontrast media
Gell & Coombs Classification
• Type I - Immediate hypersensitivity (IgEmediated)
• Type II - Cytotoxic reactions
• Type III - Immune complex (e.g. serum
sickness, drug fever)
• Type IV - Delayed hypersensitivity
Sub classification of Type IV Reactions
Pichler W. Ann Intern Med 2003;139:683-9.
Other Immunopathology of Drug
Reactions
• Pseudoallergic reactions
- Resemble type I reactions
- Due to non-IgE-mediated mast cell activation
- Examples: Opiates, vancomycin, radiocontrast
media, NSAID-urticaria
- Clinical importance: can be prevented by steroid
• Innate Immune Reactions
- Complement activation
- Bradykinin release
• Others (TEN/SJS/DRESS)
Hapten Hypothesis
• Haptens are chemically reactive small
molecules
• Undergo stable covalent binding to a larger
protein or peptide
• Covalent binding of small hapten drugs to selfproteins leads to immunogenic compounds
• Penicillin classic example
Prohapten Hypothesis
• Drug that is not chemically reactive becomes
reactive after metabolism
• Chemically reactive drug metabolite can then
bind covalently to proteins/peptides and
become immunogenic
• Sulfamethoxazole example: Metabolized to
sulfamethoxazole-nitroso (highly reactive)
• Others: Acetaminophen, phenytoin,
procainamide, halothane
Drug Presentation to T cells
Posadas SJ et al. Clin Exp Allergy 2007;37:989–999
Risk Factors for Drug Allergy
• Drug Related
- Higher dose
- Parenteral administration
- Large molecular weight agents
• Host Factors
- Female gender
- Age (less frequent in infants and elderly)
- Diseases requiring repeated courses of therapy
- Genetics
Risk Factors for Drug Allergy
• Atopy (allergy)
- Atopy NOT a risk factor for small MW agents
(e.g. beta-lactam allergy)
- Atopy is a risk factor for:
 Latex allergy
 Radiocontrast media reactions
 Severe iv penicillin anaphylaxis
Clinical Manifestation: Exanthems
• Most common cutaneous drug eruption
• Usually develops days after new medicine
• Typically described as morbilliform
“maculopapular”
• Immunopathogenesis
:Many T cell mediated
Fixed Drug Eruptions
• Mechanism unknown
• Typically develops 1-2 weeks for initial reaction but
sooner with later exposures
• Occur in same location
with each subsequent
exposure to drug
• Pleomorphic: Eczema,
erythematous papules,
hyperpigmented areas,
bullous, urticarial
• Examples: Tetracycline, NSAIDs, carbamazepime
Photoallergic Reactions
• Immune mediated: DTH reactions
• UV light alters drug: Conjugation to selfprotein
• Acute reactions usually 24-72 hrs
• Medications: Quinidine, dapsone, HCTZ
Phototoxic Reactions
• Non-immunologic
• No drug alteration by UV light
• Erythroderma minutes to hrs after light
exposure
: Vesicles with severe reactions
• Often with first exposure to drug
• Medications: Sulfonamides, tetracycline,
furosemide, HCTZ, fluoroquinolones
Drug-Induced Blistering Disorders
• Drug-Induced Pemphigus
- 80% due to thiol group-containing medication
: Captopril, penicillamine
- Flaccid blisters
• Drug-Induced Bullous Pemphigoid
- Tense bullae on extremities, trunk, and
sometime mucous membranes
- ACE-I, furosemide, penicillin, sulfasalazine
Linear IgA Bullous Dermatosis
• Most commonly with vancomycin
• Other medications
: Captopril, furosemide, lithium, TMP/SMX
• Tense blisters that mimic bullous pemphigoid
• Generally occurs within 24 hours to 15 days
following administration of the offending drug
• Vancomycin-induced LAD is not dose dependent
and the severity of the reaction does not
correlate with serum vancomycin levels
Systemic vs. Cutaneous Drug-Induced
Lupus Erythematosis (DILE)
Solensky R et al. Ann Allergy Asthma Immunol 2010;105:273e1-78.
Serum Sickness
• Mediated by immune complexes:
Heterologous antisera, snake antivenom,
Rabbit antithymocyte globulin (ATG) and
rituximab
• Clinical features: Fever, lymphadenopathy,
arthralgias, rashes, gastrointestinal symptoms,
proteinuria (some cases)
• Typically occurs after 1-3 weeks: More rapidly
in previously sensitized
Serum Sickness-Like Reactions
• Small molecular weight agents: Penicillin,
sulfonamides, thiouracils, phenytoin
• May lack features of immune complexes,
hypocomplementemia, vasculitis, renal
disease
• Cefaclor most common cause in children
- Altered metabolism leading to toxic reactive
intermediates
Drug Fever
• Caused by release of pyrogens from
phagocytes :
- can be immune complex or T cell-mediated.
• Typically 7-10 days after therapy
• Fever pattern variable
• Relieved within 48 hrs of stopping drug
Pulmonary Drug Hypersensitivity
• Pulmonary infiltrate with eosinophilia (PIE)
- Cough within 10 days of starting drug
- Migratory infiltrates
- Peripheral eosinophilia
- Antibiotics, NSAIDs most common cause of
PIE
- Nitrofurantoin most common antibiotic
Pulmonary Drug Hypersensitivity
• Amiodarone
- Pneumonitis, bronchioloitis obliterans, ARDS
- Some reactions may be immunologic
• Methotrexate: Acute granulomatous ILD
• Chemotherapeutics
- ILD from bleomycin, mitomycin-C, busulfan,
cyclophosphamide, nirosourea
• Nitrofurantoin: Pleural effusion, pneumonitis,
fibrosis
Misc. Drug Allergy Syndromes
• Immunologic nephropathy
- Interstitial nephritis: +Urine eosinophils, benzyl
penicillin, methicillin or sulfonamides
- Membranous glomerulonephritis: gold, penicillamine,
allopurinol
• Aseptic meningitis: NSAID’s, IVIG, antibiotics
• Immunologic hepatitis: Halothane, para-aminosalacylic
acid, sulfonamides and phenothiazines
Severe Cutaneous Adverse Reactions
(SCAR)
• AGEP
• DRESS
• SJS/TEN
Acute Generalized Eczematous Pustulosis
(AGEP)
• Characterized by fine
pustules, fever, and neutrophilia
• Rash begins in intertriginous
areas or face as edema and
erythema
 Nonfollicular sterile pustules
develop afterwards
• Atypical target lesions, blisters and oral mucosal
involvement uncommon but may confuse with
SJS or TEN
• Lesional T cells secrete high amounts of IL-8
(CXCL8)
DRESS
• Drug Rash Eosinophilia Systemic Symptoms
• Causative Drugs
: Anticonvulsants, sulfonamides, allopurinol,
minocycline, dapsone, sulfasalazine,
abacavir, nevirapine, hydroxychloroquine,
vancomycin, etc.
Clinical Features of DRESS (I)
• Rash
: Exanthem, erythroderma, erythema multiforme,
purpura
• Facial edema is diffuse and may be mistaken for
angioedema
- Genital & extremity edema
• Fever
: Vast majority of cases
• Hypotension
: Up to 40% cases
Clinical Features of DRESS (II)
• Hematologic abnormalities
- Eosinophilia in > 50%
- Anemia, neutropenia, thrombocytopenia/cytosis less common
• Hypogammaglobulinemia in some cases
Organ Involvement in DRESS
• Lymphadenopathy <30% cases
• Liver involvement in >60% cases
• Renal dysfunction < 30% cases
: 40-80% with allopurinol
• Respiratory & Cardiac less common
: Eosinophilic pneumonitis, cough, dyspnea,
pharyngitis, Pericarditis, myocarditis
Unique Aspects of DRESS
• Reaction occurs after 2-8 weeks of therapy
• Symptoms may worsen after drug
discontinued
• Symptoms may last weeks to even months
after drug discontinued
Stevens-Johnson Syndrome (SJS) and
Toxic Epidermal Necrolysis (TEN)
• SJS/TEN thought to represent a spectrum of a
single reaction
• SJS: < 10% total body surface area
Overlap SJS/TEN: 10-30% body surface area
TEN: >30% surface area involvement
SJS vs TEN
*Nikolsky’s sign
Clinical Features of SJS/TEN
• Triad
1. Mucous membrane erosions: lip, oral cavity,
conjunctiva, nasal cavity, urethra, and vagina
2. Target lesions
3. Epidermal necrosis with detachment
• Multi-organ involvement
- Gastrointestinal, hepatic, pulmonary, renal
• Mortality: SJS: < 5%; TEN: 10-50% or higher
SJS/TEN
• Higher Risk Patients
: HIV, SLE, Bone marrow transplant
• High risk agents (*newer agents)
: *Nevirapine, *lamotrigine, *sertraline,
*pantoprazole, *tramadol, carbamazepime,
phenytoin, phenobarbitol, sulfasalazine,
allopurinol, sulfonamide antibiotics, oxicamNSAID’s
• TEN usually drug-induced and glucocorticoids are
contraindicated
Penicillin Allergy (Antigens)
• Major determinant (BPO)
: 95% PCN reacts with self-proteins via
beta-lactam ring to form benzylpenicilloyl
(BPO)
• Minor determinants
- penicilloate
- penilloate
- penicillin G
Penicillin Allergy
• 90% patients with a Hx of PCN allergy will
tolerate PCN
• ~ 80% PCN allergic patients lose PCN IgE after
10 years
• 1/3 patients with vague Hx of PCN allergy are
PCN skin test positive
PCN Skin Tests
• Negative predictive value for anaphylaxis is
close to 100% if skin test negative to
penicilloylpolylysine (Pre Pen) and minor
determinants
• 10-20% of PCN-allergic patients show skin test
reactivity only to penicilloate or penilloate
: Clinical significance is unknown
Ampicillin/Amoxicillin
• Some patients have IgE antibodies directed at the Rgroup side chain (not core penicillin determinants) and
are able to tolerate other penicillin class compounds
- Frequent in Europe, rare in U.S.
- PCN skin tests negative
• Amoxicillin and ampicillin are associated with the
development of a delayed maculopapular rash in about
5-10% of patients
- not IgE-mediated
- Concomitant conditions
: EBV (infectious mono; ~100% children develop rash)
Penicillin and Cephalosporins
Share a common beta-lactam ring
Cephalosporin & PCN Allergy
• Only 2% of penicillin skin test-positive patients
react to treatment with cephalosporins: Some
fatal
• If penicillin skin testing is unavailable, and
cephalosporin needed, it may be given via graded
challenge
: Negative cephalosporin skin test appears to
predict tolerance (Romano 2004)
• Patients with a history of non-severe reaction to
penicillin rarely react to cephalosporins
Cephalosporin Allergy
• Most hypersensitivity reactions to
cephalosporins are directed at the R group
side chains rather than the beta-lactam group
• Cephalosporin allergic patients should avoid
cephalosporins with similar R-group side
chains
PCN Allergy and Monobactams
• Aztreonam (monobactam) does not crossreact with other beta-lactams
: except for ceftazidime
shares an identical R-group side chain
PCN Allergy and Carbapenems
• Moderate allergic cross-reactivity between
penicillin and carbapenems based on skin tests
: 50% PCN-allergic patients skin test positive to
imipenem (Saxon 1988)
• Clinical cross-reactivity variable but much lower
- Recent studies suggest 0-11% react
NEJM 2006;354:2835-7,
Ann Intern Med 2007;146:266-69,
JACI 2009;124:167-9.
Skin testing for Non-PCN Antibiotics
• There are no validated diagnostic tests for
evaluation of IgE-mediated allergy to
nonpenicillin antibiotics
• A negative skin test result does not rule out
the possibility of an immediate-type allergy
• Positive skin test results to a drug
concentration known to be non-irritating
suggests the presence of drug-specific IgE
Sulfonamide Allergy
• A sulfonamide is any compound that contains
a sulfonamide (SO2NH2) moiety
• Sulfonamide antimicrobial drugs are different
from other sulfonamide-containing
medications (furosemide, thiazide diuretics
and celecoxib) by virtue of an aromatic amine
at the N4 position and a substituted ring at
the N1 position
Sulfonamide Allergy
• Delayed maculopapular eruption most typical
reaction: Mechanism unclear
• Very frequent in HIV infected patients
: (44-70%)
Cross-Reactivity between
Sulfonamide Antibiotics and Nonantibiotics
• Myth about cross-reactivity between
sulfonamide antibiotics and nonantibiotic
drugs (lasix, HCTZ, sulfasalazine etc)
• Patients with sulfonamide antibiotic allergy
were more likely to react to penicillin than a
sulfonamide non-antibiotic
Strom BL et al. NEJM 2003;349:1628-35
Vancomycin: Red Man Syndrome
• Constellation of symptoms
- Pruritus, flushing, erythroderma common
- Hypotension uncommon
• Due to nonspecific histamine release that is rate
related (rare reports of IgE-anaphylaxis)
• Severity correlates with amount of histamine
released into plasma
• Severity reduced by
- reducing rate to < 500 mg/hr
- premedication with H1-antagonists
Perioperative Drug Reactions
• Neuromuscular blocking agents are most
common (succinylcholine, rocuronium,
atracurium, vecuronium, etc)
- IgE mediated or direct mast cell activation
• Other causes of IgE mediated perioperative
reactions
- Latex, barbiturates (thiopental), antibiotics
Perioperative Drug Reactions
• Dextran and hydroxyethyl starch
: Anaphylactoid reactions
• Propofol
- Rare reports including those with egg allergy
- Propofol contains egg lecithin (from egg yolk)
which contains minimal contaminant egg
protein
- One study showed 98% egg allergic children
tolerated propofol
Chemotherapeutics
• Taxanes (paclitaxel, docetaxel)
- Anaphylactoid reactions
- Pretreatment with systemic corticosteroids and
antihistamines prevents most reactions
• Platinum compounds (cisplatin, carboplatin, oxiplatin)
- IgE mediated
- typically cause hypersensitivity reactions after
completion of several treatment courses
• Asparaginase may cause anaphylactic or anaphylactoid
reactions
Local Anesthetic Allergy
• Most adverse reactions to local anesthetics are due to
nonallergic factors
- Vasovagal, anxiety
- Toxic or idiosyncratic reactions due to intravenous
epinephrine
• Local anesthetic groups
- group 1 benzoic acid esters: procaine, benzocaine
- group 2 amides: lidocaine, bupivicaine, mepivacaine
• Based on patch testing, benzoic acid esters cross-react
with each other, but not group 2 amide drugs
Local Anesthetic Allergy
• Skin tests are not adequate to diagnose
lidocaine allergy
: false positives
• Graded challenge test of choice for evaluating
potential local anesthetic allergy
Radiocontrast Media Reactions
• Mechanisms
- Anaphylactoid
: Direct mast cell activation
? IgE mediated (Allergy. 2009 Feb;64(2):234-41.)
- Delayed reactions due to type IV hypersensitivity
• Reaction rate from ionic contrast > non-ionic contrast
• No evidence that sensitivity to seafood or iodine
predisposes or is cross-reactive with RCM reactions
Radiocontrast Anaphylactoid Reactions
• Risk Factors
- Female
- Asthma
- Cardiovascular disease
- Prior reaction to RCM
• Management
- Non-ionic RCM
- *Pre-treatment
1. Prednisone 50 mg
: 13, 7, 1 hr prior
2. Diphenhydramine 50 mg
: 1 hr prior
3. Ephedrine/albuterol
4. H2-antagonists
: controversial
*Pre-treatment does not completely prevent RCM reactions
Aspirin-Exacerbated Respiratory Disease
(AERD)
• Associated with asthma, rhinitis, sinusitis,
nasal polyposis
• Symptoms with NSAIDs
: Rhinorrhea, conjunctivitis, bronchospasm
- Rarely flushing, urticaria, GI symptoms,
laryngospasm, hypotension
• Dependent on COX-1 inhibition
• COX-2 inhibitors generally safe
Pathophysiology of AERD
- Inhibition of COX-1 results in
: Inhibits PGE2 leading to ↑ leukotrienes
- ↑ urinary LTE4
↑ LTE4 and TXB2 in BAL
↑ LTC4 synthase expression in bronchial mucosa
↓ lipoxin generation
↑ cysLTR1 & cysLTR2 receptor expression
↑ response to inhaled LTD4
AERD
• Diagnosis
: Oral challenge
Inhalation of lysine-ASA
• Aspirin Desensitization
- Improvement in upper and lower airway
symptoms
- After ASA desensitization
↓ uLTE4, ↓ BHR to LTE4
↓ serum tryptase/histamine
↓ nasal expression of cysLT1 receptor
Angiotensin Converting Enzyme (ACE)
Inhibitors
• Cough
- Incidence up to 20%
- Mechanism unknown
- Angiotensin II receptor blockers (ARBs) tolerated
• Angioedema
- 0.1-0.7%, more common in African-Americans
- Usually delayed in onset: mean 1.8 yrs (Malde 2007)
- Likely des-Arg bradykinin induced
- Usually tolerate ARBs but case reports of AE with
ARBs too
Insulin
• Local Reactions
- IgE mediated
- Resolve with continued administration
• Systemic Reactions
- Usually occur after gap in insulin therapy
(ex. Gestational diabetes)
- Skin tests and desensitization may be required if
insulin therapy interrupted > 24-48 hrs
Adverse Reactions to Biologics
• Cytokine release syndrome
- Fever, rash, bronchospasm, capillary leak
syndrome, GI sxs, aseptic meningitis,
encephalopathy
- ↑ LFTs, uric acid, LDH
- Associated with rituximab (anti-CD20) &
muromunab (anti-CD3)
Adverse Reactions to Biologics
• IL-2 (aldesleukin)
- Capillary (vascular) leak syndrome
- Uncommon but potentially fatal
- Hypotension and edema due to
extravascular fluid and protein
extravasation
Monoclonal Antibody Reactions
• Anaphylaxis
- Basiliximab (chimeric anti-IL2 receptor antagonist)
- Muromonab (murine anti-CD3 mAb)
- Cetuximab (anti-EGFR)
: Due to pre-existing antibodies to an oligosaccharide,
galactose-α-1,3-galactose present on the Fab portion
of cetuximab (Chung NEJM 2008)
: most had specific IgE to cetuximab before therapy
Management of the Drug Allergic
Patient
• For most drugs no validated in vivo or in vitro
diagnostic tests are available
• If a patient requires a medication they are
allergic to options include:
1) finding an alternative medication
2) performing a graded drug challenge
3) performing drug desensitization
Drug Desensitization
• Benefit
- Established protocols for many drugs
- Relatively safe
: May be done in an office setting
: Reactions during desensitization variable depending on
drug but rarely severe
• Disadvantages
- Temporary effect (not tolerance induction)
- Need to take medicine continuously to maintain
desensitized state
- Need to repeat for every subsequent courses
Graded Challenge (Test Dose)
• A graded challenge is a procedure to
determine if a drug is safe to administer
• Intended for patients who are unlikely to be
allergic to the given drug
• In contrast to a desensitization, a graded
challenge does not modify the patient’s
response to a drug
Graded Challenge (Test Dose)
• Benefit
- Easy to perform
- Typically start with 1/100th of final dose, then
1/10th and full dose
- usually given every 30-60 minutes
- confirms or negates drug allergy history
• Disadvantages
- Potentially higher risk
Thank You!!!